The company’s Eversense device includes a fluorescence-based sensor, a mobile app and a transmitter. Senseonics’ touts its system as being the first with a long-term, implantable CGM sensor, as well as the first to have a smart transmitter.
“We are pleased that both Blue Cross Blue Shield of Massachusetts and Idaho have recognized Eversense CGM as one of their diabetes management tools and also recognize the value it brings to their patients with diabetes,” president & CEO Tim Goodnow said in prepared remarks.
“With each new coverage decision, we are able to reduce the barriers and help thousands of patients experience the freedom that Eversense brings for up to 90 days of continuous glucose readings. This kind of proactive information helps empower patients to actively manage their diabetes,” Goodnow added.
Last month, Senseonics reported on real-world data it said demonstrated the safety and lack of adverse events with its Eversense CGM.